This phase I study in patients with astrocytoma grade 4 (AG4) [15] examines whether infusions of EGFR BATs in combination with standard radiation and chemotherapy are safe and feasible and if the therapy induces systemic anti-tumor immunity. This evidence concerns the gene EGFR and neoplasm.